# Optimal Effect-site Concentration of Remifentanil for Inhibiting Response to Laryngeal Mask Airway (LMA) Removal

> **NCT01915108** · NA · COMPLETED · sponsor: **Sangjin Park** · enrollment: 128 (actual)

## Conditions studied

- Respiratory Complication

## Interventions

- **DRUG:** Remifentanil

## Key facts

- **NCT ID:** NCT01915108
- **Lead sponsor:** Sangjin Park
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07
- **Primary completion:** 2013-06
- **Final completion:** 2013-06
- **Target enrollment:** 128 (ACTUAL)
- **Last updated:** 2014-08-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01915108

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01915108, "Optimal Effect-site Concentration of Remifentanil for Inhibiting Response to Laryngeal Mask Airway (LMA) Removal". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01915108. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*